ClinicalTrials.gg
RecruitingNCT07741643Updated Nov 13, 2026

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

A Phase 1 interventional study of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 in HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma and Head and Neck Cancer, sponsored by Vanderbilt-Ingram Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Vanderbilt-Ingram Cancer Center · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 13, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck — 4 open to participants now, 4 under way, none of them phase 3. Panitumumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
6th of 10
30 · median 32
Started
2026
the only one that year
Phase 1
6 of 10
4 open now
Registered
10th of 10
by date
Lead sponsor
4 of 10
Vanderbilt-Ingram Cancer Center

Among the 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 1, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during surgery in adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled for tumor removal and neck dissection.

The main questions it aims to answer are:

  • Is the combination of Pan800 and [18F]NOTA-ABY-030 safe and well tolerated in patients undergoing surgery for HNSCC?
  • How accurately can Pan800 and [18F]NOTA-ABY-030 detect tumor tissue and cancer-positive lymph nodes when compared with final pathology results?

This is a single-arm, open-label study, so there is no comparison group.

Study Related Steps:

  • Receive an intravenous infusion of Pan800 1-2 days before surgery.
  • Receive an intravenous injection of[18F]NOTA-ABY-030 on the day of surgery.
03

Conditions studied

  • HNSCC,Larynx, Pharynx and Oral Cavity
  • Squamous Cell Carcinoma
  • Head and Neck Cancer
  • Head and Neck Surgery

Keywords

  • SCC
  • HNSCC
  • Oral Cavity
  • Fluorescent Guided Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Subjects diagnosed with any T stage or N stage squamous cell carcinoma and any subsite within the head and neck that are scheduled to undergo surgical resection and neck dissection. Subjects with recurrent disease or a new primary will be allowed.
  3. Have acceptable hematologic status, kidney function, and liver function including the following clinical results:

    • ≥ 9 gm/dL
    • White blood cell count > 3000/mm3
    • count ≥ 100,000/mm3
    • Serum creatinine ≤ 1.5 times upper reference range
    • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
  2. Evidence of prolongation on within 30 days of pan800 administration (greater than 480 ms).
  3. History of infusion reactions to monoclonal antibody therapies.
  4. History of allergies to iodine.
  5. Pregnant or breastfeeding.
  6. Magnesium or phosphorus lower than the normal institutional values and the patient is symptomatic.
  7. Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
  8. Subjects with history or evidence of interstitial pneumonitis or pulmonary fibrosis.
  9. Severe renal disease or anuria.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    5.0 mCi - [18F]NOTA-ABY-030 and 50 mg - pan800

    Drug: Panitumumab-IRDye800 · Drug: [18F]NOTA-ABY-030

Interventions

  • DrugPanitumumab-IRDye800

    Drug pages: PanitumumabStudies of PanitumumabPanitumumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IRDye800Studies of IRDye800IRDye800 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV Infusion of 50 mg dose of Panitumumab-IRDye800 (Pan800) 1-2 days before surgery.

  • Drug[18F]NOTA-ABY-030

    Single intravenous bolus injection of approximately 5 mCi (±10%) in the operating room prior to tumor removal and neck dissection.

06

What researchers measure

Primary outcomes

  1. Record and evaluate the number events considered clinically significant Grade ≥2 AEs that are considered possibly, probably, or definitely related to [¹⁸F]NOTA-ABY-030, pan800, or both agents.

    Time frame: Up to 30 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We do not plan to share individual participant data from this phase 1 study due to its exploratory nature with a new drug. Sharing individual-level data at this stage could compromise participant confidentiality and may not yield meaningful insights given the preliminary scope of the study.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2031, 58 months after the start.

Of 116 non-industry phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 61. This study's planned 58 months is above that.

Counting every sponsor, half of 272 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, last on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Aug 3, 2026
StartActual
Sep 15, 2026was Aug 2026
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
1 site added — first site in United States
Show site
  • Vanderbilt University Medical Center · Nashville, United States
Oct 19, 2026
Start date
Aug 2026→Sep 15, 2026 (actual)
moved 2 times, Oct 19, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Start date Oct 2026→Sep 15, 2026 (now actual)
  2. Oct 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Vanderbilt University Medical Center · Nashville, United States
    Start date Aug 2026→Oct 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741643
Responsible party
Eben Rosenthal (Barry and Amy Baker Professor and Department Chair, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 3, 2026
Start date
Sep 15, 2026
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 13, 2026

Study contacts

Makenna Brown
Contact
makenna.l.brown@vumc.org
6154214370
Nicole Jones
Contact
nicole.l.jones@vumc.org

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · IRDye800

Start the discussion